Lucid Diagnostics Inc (NASDAQ:LUCD) — Market Cap & Net Worth
Market Cap & Net Worth: Lucid Diagnostics Inc (LUCD)
Lucid Diagnostics Inc (NASDAQ:LUCD) has a market capitalization of $142.90 Million ($142.90 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17821 globally and #3980 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lucid Diagnostics Inc's stock price $1.09 by its total outstanding shares 131098762 (131.10 Million). Analyse Lucid Diagnostics Inc cash flow conversion to see how efficiently the company converts income to cash.
Lucid Diagnostics Inc Market Cap History: 2021 to 2026
Lucid Diagnostics Inc's market capitalization history from 2021 to 2026. Data shows change from $704.00 Million to $142.90 Million (-40.73% CAGR).
Index Memberships
Lucid Diagnostics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #492 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1738 of 3165 |
Weight: Lucid Diagnostics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lucid Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lucid Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
24.70x
Lucid Diagnostics Inc's market cap is 24.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $704.00 Million | $500.00K | -$28.08 Million | 1408.00x | N/A |
| 2022 | $178.29 Million | $377.00K | -$56.17 Million | 472.93x | N/A |
| 2023 | $184.85 Million | $2.43 Million | -$52.67 Million | 76.13x | N/A |
| 2024 | $107.33 Million | $4.35 Million | -$45.53 Million | 24.70x | N/A |
Competitor Companies of LUCD by Market Capitalization
Companies near Lucid Diagnostics Inc in the global market cap rankings as of May 5, 2026.
Key companies related to Lucid Diagnostics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Lucid Diagnostics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Lucid Diagnostics Inc's market cap moved from $704.00 Million to $ 142.90 Million, with a yearly change of -40.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $142.90 Million | 0.00% |
| 2025 | $142.90 Million | +33.14% |
| 2024 | $107.33 Million | -41.94% |
| 2023 | $184.85 Million | +3.68% |
| 2022 | $178.29 Million | -74.67% |
| 2021 | $704.00 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Lucid Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $142.90 Million USD |
| MoneyControl | $142.90 Million USD |
| MarketWatch | $142.90 Million USD |
| marketcap.company | $142.90 Million USD |
| Reuters | $142.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the… Read more